Article

3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement

2015-09-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f0e809ca-df9e-5c41-bcf5-4e19d7dfff9a
DOI: 10.1016/s0959-8049(16)31654-9

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 10 closest

3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvementDOI 10.1016/s0959-8049(16)31654-9Read

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studiesSemantic proximity Read

Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions.Semantic proximity Read

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.Semantic proximity Read

Rociletinib for EGFR-mutated Non–Small-Cell Lung CancerSemantic proximity Read

Preclinical Evidence and Clinical Cases of Azd9291 Activity in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc) Brain Metastases (Bm)Semantic proximity Read

AZD3759 for CNS metastases in EGFR-mutant lung cancer.Semantic proximity Read

6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)Semantic proximity Read

Rociletinib in EGFR-mutated non-small-cell lung cancer.Semantic proximity Read

Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR MutationsSemantic proximity Read

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.Semantic proximity Read